Aura Biosciences (NASDAQ:AURA) Sees Large Volume Increase - Here's What Happened

Key Points

• Volume spike: Trading surged to 360,737 shares on Monday (up 45% from the prior session) and the stock last traded at $8.17 versus a $7.01 close.
• Mixed analyst outlook: Coverage is varied with a consensus "Hold" and a $21.50 average target; HC Wainwright upgraded to a Buy with a $24 target while some firms maintain sell ratings.
• Insider selling amid heavy institutional ownership: Insiders sold 116,305 shares in the past 90 days (insider ownership 6.30%) even as institutions hold 96.75% of the stock; Aura has a $521.6M market cap and reported quarterly EPS of -$0.37 (beat estimates).

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) shares saw strong trading volume on Monday . 360,737 shares were traded during trading, an increase of 45% from the previous session's volume of 248,514 shares.The stock last traded at $8.17 and had previously closed at $7.01.

Wall Street Analyst Weigh In

AURA has been the subject of several analyst reports. Wall Street Zen raised Aura Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, April 4th. HC Wainwright boosted their price objective on Aura Biosciences from $22.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, April 29th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Aura Biosciences in a report on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $21.50.

Aura Biosciences Stock Performance

The company has a 50 day simple moving average of $6.49 and a 200 day simple moving average of $5.99. The company has a market capitalization of $521.63 million, a PE ratio of -4.53 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.06. As a group, equities research analysts anticipate that Aura Biosciences, Inc. will post -1.63 EPS for the current year.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 15,890 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $5.05, for a total transaction of $80,244.50. Following the transaction, the chief technology officer directly owned 181,397 shares in the company, valued at $916,054.85. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Janet Jill Hopkins sold 20,401 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total value of $103,229.06. Following the transaction, the insider owned 232,284 shares in the company, valued at $1,175,357.04. This trade represents a 8.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 116,305 shares of company stock valued at $611,230 over the last ninety days. 6.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Aura Biosciences by 16.7% in the third quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company's stock valued at $17,863,000 after acquiring an additional 413,001 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Aura Biosciences by 67.1% in the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock valued at $13,257,000 after acquiring an additional 850,000 shares in the last quarter. Levin Capital Strategies L.P. raised its stake in shares of Aura Biosciences by 8.8% in the third quarter. Levin Capital Strategies L.P. now owns 1,627,274 shares of the company's stock valued at $10,057,000 after acquiring an additional 131,714 shares in the last quarter. State Street Corp raised its stake in shares of Aura Biosciences by 5.4% in the fourth quarter. State Street Corp now owns 926,534 shares of the company's stock valued at $5,050,000 after acquiring an additional 47,663 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of Aura Biosciences by 0.6% in the third quarter. UBS Group AG now owns 896,811 shares of the company's stock valued at $5,542,000 after acquiring an additional 5,783 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.